ENXTPA:IPHBiotechs
Innate Pharma (ENXTPA:IPH) Semi Annual Loss Of €21.34m Reinforces Bearish Narratives
Innate Pharma (ENXTPA:IPH) has just posted its FY 2025 first half numbers, with revenue of €4.86 million and a basic EPS loss of €0.25, alongside net income excluding extra items of a €21.34 million loss. Over the last three reported halves, revenue has moved from €12.35 million in 1H 2024 to €7.78 million in 2H 2024 and €4.86 million in 1H 2025. Basic EPS losses were €0.31, €0.30 and €0.25 respectively. This provides a clearer view of how top line and per share losses have tracked as the...